Vera Therapeutics, Inc.(VERA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VERA Vera Therapeutics, Inc.

Market Closed 11-06 16:00:00 EST

29.79

-0.35

-1.18%

盘后30.37

+0.59+1.96%

19:43 EST

High30.84	Low28.04	Vol2.08M
Open30.48	D1 Closing30.14	Amplitude9.30%
Mkt Cap2.14B	Tradable Cap1.56B	Total Shares71.71M
T/O61.75M	T/O Rate3.97%	Tradable Shares52.39M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VERA","market":"US","secType":"STK","nameCN":"Vera Therapeutics, Inc.","latestPrice":29.785,"timestamp":1793998800000,"preClose":30.14,"halted":0,"volume":2078214,"hourTrading":{"tag":"盘后","latestPrice":30.37,"preClose":29.785,"latestTime":"19:43 EST","volume":3671,"amount":109685.5055,"timestamp":1794012190266,"change":0.585,"changeRate":0.019641,"amplitude":0.019641},"delay":0,"changeRate":-0.01177836761778369,"floatShares":52394100,"shares":71713905,"eps":-5.898389,"marketStatus":"Market Closed","change":-0.355,"latestTime":"11-06 16:00:00 EST","open":30.48,"high":30.84,"low":28.0371,"amount":61745259.192648,"amplitude":0.092996,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.898389,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1794214800000},"marketStatusCode":7,"adr":0,"listingDate":1620964800000,"exchange":"NASDAQ","adjPreClose":30.14,"preHourTrading":{"tag":"盘前","latestPrice":30.53,"preClose":30.14,"latestTime":"09:29 EST","volume":5809,"amount":177034.764505,"timestamp":1793975399999,"change":0.39,"changeRate":0.01294,"amplitude":0.0501},"postHourTrading":{"tag":"盘后","latestPrice":30.37,"preClose":29.785,"latestTime":"19:43 EST","volume":3671,"amount":109685.5055,"timestamp":1794012190266,"change":0.585,"changeRate":0.019641,"amplitude":0.019641},"volumeRatio":1.2700611413662959,"impliedVol":0.8645,"impliedVolPercentile":0.5339},"requestUrl":"/m/hq/s/VERA","defaultTab":"news","newsList":[{"id":"2681840027","title":"Analysts Are Upgrading Vera Therapeutics, Inc. (NASDAQ:VERA) After Its Latest Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2681840027","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681840027?lang=en_us&edition=fundamental","pubTime":"2026-11-08 20:09","pubTimestamp":1794139760,"startTime":"0","endTime":"0","summary":"SSimply Wall StNovember 8, 2026","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/analysts-are-upgrading-vera-therapeutics-inc-nasdaqvera-afte","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/analysts-are-upgrading-vera-therapeutics-inc-nasdaqvera-afte","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TQQY","ONEQ","GPIQ","TECS","IYW","03086","QQQE","QQQ","VERA","QQQA","TQQQ",".IXIC","QLD","QQQJ","BK4588","QQQM","QID","QYLG","LU2324357040.USD","BK4139","JEPQ","NDX","SQQQ","NQmain","MNQmain","BK4585","FTEC","QDTE","QQQY","PSQ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681190298","title":"Does Early Trutakna Sales Change The Bull Case For Vera Therapeutics (VERA)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2681190298","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681190298?lang=en_us&edition=fundamental","pubTime":"2026-11-07 14:29","pubTimestamp":1794032942,"startTime":"0","endTime":"0","summary":"SSasha JovanovicNovember 7, 2026","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/does-early-trutakna-sales-change-the-bull-case-for-vera-ther","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/does-early-trutakna-sales-change-the-bull-case-for-vera-ther","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["VERA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681195008","title":"Bank of America Securities Remains a Buy on Vera Therapeutics (VERA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2681195008","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681195008?lang=en_us&edition=fundamental","pubTime":"2026-11-07 13:35","pubTimestamp":1794029754,"startTime":"0","endTime":"0","summary":"Bank of America Securities analyst Dina Ramadane maintained a Buy rating on Vera Therapeutics yesterday. The company’s shares closed yesterday at $...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-remains-a-buy-on-vera-therapeutics-vera-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-remains-a-buy-on-vera-therapeutics-vera-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0208291251.USD","LU1894683348.USD","LU0320765489.SGD","IYF","LU0130102774.USD","LU1804176565.USD","VFH","LU0130518102.USD","LU0070302665.USD","LU0149725797.USD","LU0971096721.USD","IE00BLSP4452.SGD","FNCL","LU2129689431.USD","VERA","BAC","XLF","BK4534","IYG","LU1280957306.USD","LU2129689514.USD","BK4504","LU0052756011.USD","LU1496350171.SGD","IE00BKVL7J92.USD","LU0648001328.SGD","PGF","IE00BBT3K403.USD","LU0053666078.USD","LU0106831901.USD","LU2324357040.USD","FTXO","TFNS","LU1035773651.USD","IE00B1BXHZ80.USD","UYG","LU0234570918.USD","LU0477156953.USD","LU2129689605.HKD","LU0256863811.USD","BK4139","LU1880398471.USD","LU0306807586.USD","LU1668664300.SGD","IE00BLSP4239.USD","LU0321505868.SGD","LU0170899867.USD","BK4581","KBWB","IE0002270589.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681949358","title":"Vera Therapeutics Grants 14,900 Stock Options, 7,450 RSUs to Three New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2681949358","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681949358?lang=en_us&edition=fundamental","pubTime":"2026-11-07 05:06","pubTimestamp":1793999171,"startTime":"0","endTime":"0","summary":"Vera Therapeutics grants 14,900 stock options, 7,450 RSUs to three new employeesVera Therapeutics granted equity awards to three new employees on November 2, 2026, under its 2024 Inducement Plan.Award","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261106:nNDLYqgHh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3D17.EUR","IE00BN0W2V16.EUR","IE00BQXX3F31.USD","LU2210150020.SGD","LU2095319765.USD","LU2324357040.USD","BK4539","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","IE00BQXX3C00.GBP","BK4588","SG9999014005.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4139","IE00BGHQF748.EUR","BK4585","SG9999014039.USD","SG9999014021.USD","BK4112","LU0314104364.USD","LU2210149790.SGD","NDAQ","VERA","BCDF","SG9999014013.SGD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681189202","title":"Vera Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2681189202","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681189202?lang=en_us&edition=fundamental","pubTime":"2026-11-07 05:05","pubTimestamp":1793999100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261106:nTUABFMTNB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4588","BK4139","BK4585","VERA","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681894137","title":"Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2681894137","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681894137?lang=en_us&edition=fundamental","pubTime":"2026-11-07 05:05","pubTimestamp":1793999100,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., Nov.  06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on November 2, 2026, the Compensation Committee of the Board of Directors (Compensatio","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/11/06/3397887/0/en/vera-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","BK4539","BK4139","VERA","BK4588","LCLG","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681893441","title":"Vera Therapeutics is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2681893441","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681893441?lang=en_us&edition=fundamental","pubTime":"2026-11-07 00:21","pubTimestamp":1793982060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VERA/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681686500","title":"Vera Therapeutics price target lowered to $66 from $76 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2681686500","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681686500?lang=en_us&edition=fundamental","pubTime":"2026-11-06 20:07","pubTimestamp":1793966862,"startTime":"0","endTime":"0","summary":"Guggenheim lowered the firm’s price target on Vera Therapeutics (VERA) to $66 from $76 and keeps a Buy rating on the shares. Published first on The...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-price-target-lowered-to-66-from-76-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-price-target-lowered-to-66-from-76-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VERA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681486394","title":"Wedbush Lowers Price Target on Vera Therapeutics to $29 From $34, Keeps Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2681486394","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681486394?lang=en_us&edition=fundamental","pubTime":"2026-11-06 19:47","pubTimestamp":1793965642,"startTime":"0","endTime":"0","summary":"Vera Therapeutics (VERA) has an average rating of buy and mean price target of $73.14, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VERA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681683908","title":"Vera Therapeutics price target lowered to $75 from $90 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2681683908","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681683908?lang=en_us&edition=fundamental","pubTime":"2026-11-06 19:21","pubTimestamp":1793964060,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on Vera Therapeutics (VERA) to $75 from $90 and keeps a Buy rating on the shares following the Q3 r...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-price-target-lowered-to-75-from-90-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-price-target-lowered-to-75-from-90-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VERA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681885284","title":"Vera Therapeutics, Inc. Reports Results for the Quarter Ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2681885284","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681885284?lang=en_us&edition=fundamental","pubTime":"2026-11-06 06:41","pubTimestamp":1793918484,"startTime":"0","endTime":"0","summary":"Vera Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings SummaryVera Therapeutics, Inc.VERA.OQreported a quarterly adjusted loss of $1.30 per share for the quarter ended S","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nL5N46M3E1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","BK4539","BK4588","VERA","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681300781","title":"Vera Therapeutics Reports Narrower-than-Expected Q3 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2681300781","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681300781?lang=en_us&edition=fundamental","pubTime":"2026-11-06 05:15","pubTimestamp":1793913353,"startTime":"0","endTime":"0","summary":"CORRECTED-Vera Therapeutics reports narrower-than-expected Q3 lossCorrects headline, second Overview bullet to remove reference to loss narrowingOverviewU.S. biotechnology firm's Q3 net product revenu","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nL2N46M1GB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","VERA","ZVRA","BK4007","LU2324357040.USD","MIRM","BK4539","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681002571","title":"Vera Therapeutics Q3 EPS $(1.30) Beats $(1.62) Estimate, Sales $10.277M Beat $3.398M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2681002571","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681002571?lang=en_us&edition=fundamental","pubTime":"2026-11-06 05:09","pubTimestamp":1793912941,"startTime":"0","endTime":"0","summary":"Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(1.30) per share which beat the analyst consensus estimate of $(1.62) by 19.75 percent. This is a 3.17 percent decrease over losses of $(1.26) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/11/62950349/vera-therapeutics-q3-eps-1-30-beats-1-62-estimate-sales-10-277m-beat-3-398m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Vera Therapeutics Q3 EPS $(1.30) Beats $(1.62) Estimate, Sales $10.277M Beat $3.398M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681000465","title":"Vera Therapeutics Q3 Net Income USD -93.711 Million Vs. IBES Estimate USD -117.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2681000465","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681000465?lang=en_us&edition=fundamental","pubTime":"2026-11-06 05:02","pubTimestamp":1793912521,"startTime":"0","endTime":"0","summary":"BRIEF-Vera Therapeutics Q3 Net Income USD -93.711 Million Vs. IBES Estimate USD -117.1 MillionNov 05 (Reuters) - Vera Therapeutics Q3 operating income USD -95.702 million vs. IBES estimate USD -119 million.Q3 operating expenses USD 105.979 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nPLXZRN4XQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2324357040.USD","BK4139","BK4539","VERA","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681004835","title":"Vera Therapeutics Q3 Operating Expenses USD 105.979 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2681004835","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681004835?lang=en_us&edition=fundamental","pubTime":"2026-11-06 05:01","pubTimestamp":1793912461,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nPLXZRN4XQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VERA","BK4585","BK4539","BK4588","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681045530","title":"Press Release: Vera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2681045530","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681045530?lang=en_us&edition=fundamental","pubTime":"2026-11-06 05:01","pubTimestamp":1793912460,"startTime":"0","endTime":"0","summary":"following July 7 accelerated approval by the U.S. Food and Drug. Administration  with approximately 700 Patient Start Forms  to. date and $10.3 million of net product revenue in Q3.-- ORIGIN 3 final efficacy analysis demonstrated stabilization of kidney. function and a 76% reduction in risk of composite kidney disease. progression versus placebo through two years; data was presented as a. late-breaking oral presentation at the opening plenary session at ASN. Kidney Week 2026 with a simultaneous publication in The New England. -- Completed supplemental Biologics License Application  submission to. the FDA for full approval of TRUTAKNA in adults with primary IgAN.-- Management to host a live investor webcast at 4:30 p.m. ET on November 5,proteinuria in adults with primary IgAN at risk for disease progression.There are approximately 160,000 diagnosed IgAN patients in the U.S.,-- Launched TRUTAKNA in the U.S., drawing on a cross-functional team. experienced in rare disease and kidney thera","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4022","R","BK4588","BK4585","LU2324357040.USD","BK4232","BK4139","VERA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679220380","title":"How Positive Trial Results Will Impact Vera Therapeutics Stock (VERA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2679220380","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679220380?lang=en_us&edition=fundamental","pubTime":"2026-10-31 13:38","pubTimestamp":1793425136,"startTime":"0","endTime":"0","summary":"Vera Therapeutics reported that the ORIGIN 3 trial of TRUTAKNA in adults with primary IgA nephropathy met all primary and prespecified endpoints, with statistically significant reductions in proteinuria and multiple kidney disease biomarkers, and a safety profile generally comparable to placebo.\nThe final ORIGIN 3 data, presented at ASN Kidney Week and published in The New England Journal of Medicine, reinforces TRUTAKNA’s positioning as a potential disease modifying IgA nephropathy therapy,...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/how-positive-trial-results-will-impact-vera-therapeutics-sto","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/how-positive-trial-results-will-impact-vera-therapeutics-sto","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","BK4588","LU2324357040.USD","BK4539","VERA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174833894","title":"Earning Preview: Vera Therapeutics, Inc. this quarter’s revenue is expected to increase by 0%, and institutional views are bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1174833894","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174833894?lang=en_us&edition=fundamental","pubTime":"2026-10-29 22:42","pubTimestamp":1793284958,"startTime":"0","endTime":"0","summary":"Abstract Vera Therapeutics, Inc. will post its quarterly results on November 05, 2026 Post-Mkt, with investor attention centered on early commercial revenue signals, operating spend trajectory, and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Earning Preview: Vera Therapeutics, Inc. this quarter’s revenue is expected to increase by 0%, and institutional views are bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678110360","title":"Leerink Partners Reaffirms Their Hold Rating on Vera Therapeutics (VERA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2678110360","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678110360?lang=en_us&edition=fundamental","pubTime":"2026-10-27 21:36","pubTimestamp":1793108161,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst maintained a Hold rating on Vera Therapeutics today and set a price target of $34.00. In addition to Leerink Partners, Ver...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/leerink-partners-reaffirms-their-hold-rating-on-vera-therapeutics-vera-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/leerink-partners-reaffirms-their-hold-rating-on-vera-therapeutics-vera-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VERA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678133994","title":"Vera Therapeutics (VERA) Stock Dropped, So What Is Behind The Move?","url":"https://stock-news.laohu8.com/highlight/detail?id=2678133994","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678133994?lang=en_us&edition=fundamental","pubTime":"2026-10-25 21:31","pubTimestamp":1792935068,"startTime":"0","endTime":"0","summary":"Vera Therapeutics (VERA) drew fresh attention after releasing final Phase III ORIGIN 3 data for TRUTAKNA in IgA nephropathy, showing statistically significant efficacy across all prespecified endpoints, alongside a generally favorable safety profile.\nAgainst this backdrop, Vera Therapeutics’ share price has retreated, with the 30-day share price return down 13.98% and the year-to-date share price return down 42.43%, even though the three-year total shareholder return is up 180.46%. This...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/vera-therapeutics-vera-stock-dropped-so-what-is-behind-the-m-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/vera-therapeutics-vera-stock-dropped-so-what-is-behind-the-m-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BK4139","BK4539","BK4585","VERA","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.veratx.com","stockEarnings":[{"period":"1week","weight":-0.0386},{"period":"1month","weight":-0.0154},{"period":"3month","weight":-0.0944},{"period":"6month","weight":-0.177},{"period":"1year","weight":0.181},{"period":"ytd","weight":-0.4118}],"compareEarnings":[{"period":"1week","weight":-0.027},{"period":"1month","weight":-0.0539},{"period":"3month","weight":-0.0491},{"period":"6month","weight":-0.0032},{"period":"1year","weight":0.0969},{"period":"ytd","weight":0.0783}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":0.057587},{"month":2,"riseRate":0.4,"avgChangeRate":0.015839},{"month":3,"riseRate":0.4,"avgChangeRate":-0.047765},{"month":4,"riseRate":0,"avgChangeRate":-0.103447},{"month":5,"riseRate":0.2,"avgChangeRate":-0.049498},{"month":6,"riseRate":0.5,"avgChangeRate":0.171762},{"month":7,"riseRate":0.666667,"avgChangeRate":0.072704},{"month":8,"riseRate":0.666667,"avgChangeRate":0.026207},{"month":9,"riseRate":0.5,"avgChangeRate":0.065302},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.066272},{"month":11,"riseRate":0.666667,"avgChangeRate":0.237631},{"month":12,"riseRate":0.6,"avgChangeRate":0.07812}],"exchange":"NASDAQ","name":"Vera Therapeutics, Inc.","nameEN":"Vera Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vera Therapeutics, Inc.(VERA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vera Therapeutics, Inc.(VERA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vera Therapeutics, Inc.,VERA,Vera Therapeutics, Inc.股票,Vera Therapeutics, Inc.股票老虎,Vera Therapeutics, Inc.股票老虎国际,Vera Therapeutics, Inc.行情,Vera Therapeutics, Inc.股票行情,Vera Therapeutics, Inc.股价,Vera Therapeutics, Inc.股市,Vera Therapeutics, Inc.股票价格,Vera Therapeutics, Inc.股票交易,Vera Therapeutics, Inc.股票购买,Vera Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vera Therapeutics, Inc.(VERA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vera Therapeutics, Inc.(VERA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}